What are the key takeaways from this Axial Podcast episode?

Key insights include: **Early Commercial Analysis:** Biopharma companies routinely delay commercial assessments until Phase 2 or later, then discover they selected the wrong subpopulation, comparators, or indication — too late to course-correct. Running automated commercial analysis at the preclinical stage, when development paths still branch freely, prevents costly late-stage pivots and improves trial design decisions before resources are committed.; **Indication Prioritization at Scale:** Standard practice narrows 100 potential indications down to 5 for detailed review, leaving 95 unexamined. Automating competitive landscape synthesis, epidemiology pulls, and pricing benchmarks makes it feasible to analyze all 100 at low cost, surfacing non-obvious market gaps that a single analyst working manually would never reach within a project budget.; **Forecasting as Process, Not Output:** The precise revenue number in a forecast — whether $1B or $2B — matters less than the structured thinking the forecasting process forces. Building a forecast compels teams to define patient subtypes, identify required efficacy benchmarks, map competitive line-of-therapy dynamics, and clarify what clinical profile is actually needed to capture meaningful market share.

What did Alex Telford discuss on Axial Podcast?

Alex Telford, founder of six-month-old Convoke, explains how LLMs now make it feasible to automate biopharma commercial assessments — competitive intelligence, revenue forecasting, and indication selection — tasks previously requiring $300/hour consultants and months of manual Excel and PowerPoint work. Key topics include: **Early Commercial Analysis:** Biopharma companies routinely delay commercial assessments until Phase 2 or later, then discover they selected the wrong subpopulation, comparators, or indication — too late to course-correct. Running automated commercial analysis at the preclinical stage, when development paths still branch freely, prevents costly late-stage pivots and improves trial design decisions before resources are committed.; **Indication Prioritization at Scale:** Standard practice narrows 100 potential indications down to 5 for detailed review, leaving 95 unexamined. Automating competitive landscape synthesis, epidemiology pulls, and pricing benchmarks makes it feasible to analyze all 100 at low cost, surfacing non-obvious market gaps that a single analyst working manually would never reach within a project budget..

How long is this episode of Axial Podcast?

This episode is 57 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Axial Podcast

AI Workflows for Biopharma with Alex Telford

March 23, 2025

57 min episode · 2 min read

Alex Telford

Episode

57 min

Read time

2 min

Topics

Productivity, Investing, Startups

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Early Commercial Analysis: Biopharma companies routinely delay commercial assessments until Phase 2 or later, then discover they selected the wrong subpopulation, comparators, or indication — too late to course-correct. Running automated commercial analysis at the preclinical stage, when development paths still branch freely, prevents costly late-stage pivots and improves trial design decisions before resources are committed.
✓Indication Prioritization at Scale: Standard practice narrows 100 potential indications down to 5 for detailed review, leaving 95 unexamined. Automating competitive landscape synthesis, epidemiology pulls, and pricing benchmarks makes it feasible to analyze all 100 at low cost, surfacing non-obvious market gaps that a single analyst working manually would never reach within a project budget.
✓Forecasting as Process, Not Output: The precise revenue number in a forecast — whether $1B or $2B — matters less than the structured thinking the forecasting process forces. Building a forecast compels teams to define patient subtypes, identify required efficacy benchmarks, map competitive line-of-therapy dynamics, and clarify what clinical profile is actually needed to capture meaningful market share.
✓Capital-Constrained Strategy: Small biotechs operating with limited runway should not optimize for maximum NPV or largest addressable market. Binary survival dynamics mean prioritizing probability of success, creating value inflection points at discrete milestones, and monetizing those milestones to extend runway — a fundamentally different decision framework than large pharma portfolio management, where expected-value calculations across many assets apply.
✓Two-Cultures Problem in Pharma Software: The intersection of people who deeply understand pharma workflows and people who build high-quality software is extremely small. Pharma-native founders build products with poor engineering; tech-native founders target visible drug discovery problems and miss operational white space — areas like CRO invoice auditing, competitive intelligence automation, and revenue forecasting — that only become visible after years working inside the industry.

What It Covers

Alex Telford, founder of six-month-old Convoke, explains how LLMs now make it feasible to automate biopharma commercial assessments — competitive intelligence, revenue forecasting, and indication selection — tasks previously requiring $300/hour consultants and months of manual Excel and PowerPoint work.

Key Questions Answered

•Early Commercial Analysis: Biopharma companies routinely delay commercial assessments until Phase 2 or later, then discover they selected the wrong subpopulation, comparators, or indication — too late to course-correct. Running automated commercial analysis at the preclinical stage, when development paths still branch freely, prevents costly late-stage pivots and improves trial design decisions before resources are committed.
•Indication Prioritization at Scale: Standard practice narrows 100 potential indications down to 5 for detailed review, leaving 95 unexamined. Automating competitive landscape synthesis, epidemiology pulls, and pricing benchmarks makes it feasible to analyze all 100 at low cost, surfacing non-obvious market gaps that a single analyst working manually would never reach within a project budget.
•Forecasting as Process, Not Output: The precise revenue number in a forecast — whether $1B or $2B — matters less than the structured thinking the forecasting process forces. Building a forecast compels teams to define patient subtypes, identify required efficacy benchmarks, map competitive line-of-therapy dynamics, and clarify what clinical profile is actually needed to capture meaningful market share.
•Capital-Constrained Strategy: Small biotechs operating with limited runway should not optimize for maximum NPV or largest addressable market. Binary survival dynamics mean prioritizing probability of success, creating value inflection points at discrete milestones, and monetizing those milestones to extend runway — a fundamentally different decision framework than large pharma portfolio management, where expected-value calculations across many assets apply.
•Two-Cultures Problem in Pharma Software: The intersection of people who deeply understand pharma workflows and people who build high-quality software is extremely small. Pharma-native founders build products with poor engineering; tech-native founders target visible drug discovery problems and miss operational white space — areas like CRO invoice auditing, competitive intelligence automation, and revenue forecasting — that only become visible after years working inside the industry.

Notable Moment

Telford describes a recurring consulting pattern where a pharma team pays $100,000–$200,000 to rebuild a commercial analysis from scratch because staff turnover erased institutional memory of the previous report — the same work repeated at full cost with no reuse of existing findings.

Know someone who'd find this useful?

Episode Transcript

Welcome to the Axial podcast. Axial is an early stage investment firm based in San Francisco. We partner with great founders and inventors investing in early stage life science companies often when they are no more than an idea. Axial is fanatical about helping the right venture who's compelled to build their own and journey business. Hey, Alex. Thank you for doing this. I really appreciate you taking the time to have a conversation, with me about, your story and Convoke, and I know it's a little late on your end. But maybe to start off, you can just introduce yourself and what Convoke does. Sure. So Alex Telford. I am the founder of Convoke and, been working on the company for just about six months now. So the the real vision of of Convoke is to, you know, at a very high level is to, just increase the capital efficiency of the biotech industry. But we're focused on the sort of commercial, assessment portion of of, of putting together, actually, let me let me restart that. So we're focused on putting together of commercial assessments to support the scientific rationale for developing a drug. So I used to work as a consultant for seven years. And when I was a consultant, you know, for biotechs and pharma companies, most of what I would do was was helping put together these these sort of commercial analysis. So you're looking at the unmet need. You're looking at the competitive landscape. You're looking at the pricing of a drug. There are all these different kind of, metrics you'll look at to decide whether or not a commercial opportunity is is worth it. But the big problem with that is it's very labor intensive to put together these analyses. You know, you have to manually pull data from, you know, various different sources and do the, you know, reconcile drug names that have all sorts of different drug names between, like, clinical trials and papers. And, it's all very manual press in Excel, and then you put the reports in PowerPoint. And as soon as you prepare the PowerPoint reports, they're out of date. And, this this makes it extremely labor intensive and expensive to put together these analyses. So they often get done too late in development. So you have a lot of cases that I saw when I was a consultant where a company would, you know, they wouldn't do a commercial analysis or proper commercial analysis until quite late in development. And then they would realize that, you know, they've made some mistakes or they chose the wrong subpopulation. They chose the wrong comparators. They would have liked to develop it for, you know, different sort of indication or development plan, but now it's too late to go back. And so that's kind of the problem that I I wanna help solve, you know, bringing these commercial inputs earlier into the development process and improving the decision quality in the …

Get the full transcript (10,448 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Axial Podcast transcripts →